23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

AI drug developer raises $5 billion in new round

The British AI drug developer Isomorphic Labs has raised $5 billion in an oversubscribed Series C funding round.
Advertisement

The financing round for Isomorphic, which specialises in developing drugs using artificial intelligence, was led by investors Greenoaks and Sequoia Capital.

Isomorphic Labs’ Drug Design Engine (IsoDDE) is a system that uses different AI models, with the ambition of developing drugs for multiple therapeutic areas. The AI models are combined with the company's researchers to optimise AI-driven drug development into potential candidates.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.062|instance-web03